Expanding Medicare coverage for glucagon-like peptide 1 (GLP-1) receptor agonists could significantly reduce obesity-related ...

What happens to your body after you stop taking Ozempic has been revealed, after the use of weight loss medications has ...

Experts express alarm that GLP-1 RAs may trigger or worsen eating disorders. But is there any role they might play in binge ...

Both glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) are associated with a reduced risk for Alzheimer disease and related dementias (ADRDs ...

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep medicine.

But, like all medications, there are side effects to using both Ozempic and Mounjaro with several celebrities sharing their ...

Topline data were announced from a phase 3 trial evaluating orforglipron in adults with T2D and inadequate glycemic control with diet and exercise alone.

Stimulating a receptor in adipocytes enhanced energy expenditure and caused sustained weight loss in mice, offering targets ...

Title: ALG-055009, a potent and selective thyroid hormone receptor beta agonist for the treatment of metabolic ...

When you’re on GLP-1 medications that constant nagging about hunger and cravings, also known as “food noise”, finally ...

Among US adults without diabetes, the use of GLP-1 RAs increased from 2018 to 2022, reaching annual prevalence of 0.4% in 2022.

SGLT2 inhibitors and GLP-1RAs yielded lower risks for COPD exacerbation than DPP-4 inhibitors among patients with type 2 diabetes.